Chary Lopez-Pedrera

Summary

Country: Spain

Publications

  1. ncbi request reprint Antiphospholipid syndrome and tissue factor: a thrombotic couple
    Ch Lopez-Pedrera
    Research Unit and Rheumatology Department, Reina Sofia Hospital, Cordoba, Spain
    Lupus 15:161-6. 2006
  2. doi request reprint Novel biomarkers of atherosclerosis and cardiovascular risk in autoimmune diseases: Genomics and proteomics approaches
    Chary Lopez-Pedrera
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Cordoba, Spain
    Proteomics Clin Appl 3:213-25. 2009
  3. ncbi request reprint Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches
    Chary Lopez-Pedrera
    Maimónides Institute for Research in Biomedicine of Córdoba, Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain
    Rheumatology (Oxford) 55:2096-2108. 2016
  4. doi request reprint Immunotherapy in antiphospholipid syndrome
    Ch Lopez-Pedrera
    Maimonides Institute for Research in Biomedicine of Cordoba IMIBIC, Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain Electronic address
    Int Immunopharmacol 27:200-8. 2015
  5. pmc Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches
    Chary Lopez-Pedrera
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Instituto de Investigacion Biomédica de Córdoba, Cordoba, Spain
    J Biomed Biotechnol 2010:. 2010
  6. ncbi request reprint To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer
    Chary Lopez-Pedrera
    Unidad de Investigacion, Hospital Reina Sofia, e Instituto Manimónides de Investigación Biomédica de Córdoba IMIBIC, Cordoba, Spain
    Curr Drug Targets 13:829-41. 2012
  7. ncbi request reprint Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets
    Chary Lopez-Pedrera
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Cordoba, Spain
    Proteomics 6:S293-9. 2006
  8. doi request reprint Potential use of statins in the treatment of antiphospholipid syndrome
    Chary Lopez-Pedrera
    Unidad de Investigacion, Hospital Universitario Reina Sofía e Instituto Manimónides de Investigación Biomédica de Córdoba IMIBIC, Cordoba, Spain
    Curr Rheumatol Rep 14:87-94. 2012
  9. pmc Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions
    Chary Lopez-Pedrera
    Unidad de Investigación e Instituto Maimónides de Investigación Biomédica de Córdoba IMIBIC, Hospital Universitario Reina Sofia, Avda Menendez Pidal s n, 14004 Cordoba, Spain
    Clin Dev Immunol 2012:974648. 2012
  10. doi request reprint Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases
    C Lopez-Pedrera
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Cordoba, Spain
    Lupus 17:904-15. 2008

Collaborators

Detail Information

Publications42

  1. ncbi request reprint Antiphospholipid syndrome and tissue factor: a thrombotic couple
    Ch Lopez-Pedrera
    Research Unit and Rheumatology Department, Reina Sofia Hospital, Cordoba, Spain
    Lupus 15:161-6. 2006
    ....
  2. doi request reprint Novel biomarkers of atherosclerosis and cardiovascular risk in autoimmune diseases: Genomics and proteomics approaches
    Chary Lopez-Pedrera
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Cordoba, Spain
    Proteomics Clin Appl 3:213-25. 2009
    ..The pharmacogenomics and pharmacoproteomics studies given over to the analysis of ancient and new drugs used to relieve the physiopathology associated to these complex diseases are also discussed. ..
  3. ncbi request reprint Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches
    Chary Lopez-Pedrera
    Maimónides Institute for Research in Biomedicine of Córdoba, Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain
    Rheumatology (Oxford) 55:2096-2108. 2016
    ..We further discuss new therapies aimed at restoring the oxidative stress balance and subsequently to tackle atherothrombosis in APS and SLE...
  4. doi request reprint Immunotherapy in antiphospholipid syndrome
    Ch Lopez-Pedrera
    Maimonides Institute for Research in Biomedicine of Cordoba IMIBIC, Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain Electronic address
    Int Immunopharmacol 27:200-8. 2015
    ..Current best practice in use of these treatments is discussed. ..
  5. pmc Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches
    Chary Lopez-Pedrera
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Instituto de Investigacion Biomédica de Córdoba, Cordoba, Spain
    J Biomed Biotechnol 2010:. 2010
    ..The focus of the present paper is to summarize recent evidence showing the role of cytokines in the development of AT in SLE and the rationale, and safety concerns, in the use of combined therapy to prevent AT and cardiovascular disease...
  6. ncbi request reprint To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer
    Chary Lopez-Pedrera
    Unidad de Investigacion, Hospital Reina Sofia, e Instituto Manimónides de Investigación Biomédica de Córdoba IMIBIC, Cordoba, Spain
    Curr Drug Targets 13:829-41. 2012
    ....
  7. ncbi request reprint Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets
    Chary Lopez-Pedrera
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Cordoba, Spain
    Proteomics 6:S293-9. 2006
    ....
  8. doi request reprint Potential use of statins in the treatment of antiphospholipid syndrome
    Chary Lopez-Pedrera
    Unidad de Investigacion, Hospital Universitario Reina Sofía e Instituto Manimónides de Investigación Biomédica de Córdoba IMIBIC, Cordoba, Spain
    Curr Rheumatol Rep 14:87-94. 2012
    ..Nevertheless, larger randomized trials are needed to validate the role of statins in the treatment of this autoimmune disease...
  9. pmc Cardiovascular risk in systemic autoimmune diseases: epigenetic mechanisms of immune regulatory functions
    Chary Lopez-Pedrera
    Unidad de Investigación e Instituto Maimónides de Investigación Biomédica de Córdoba IMIBIC, Hospital Universitario Reina Sofia, Avda Menendez Pidal s n, 14004 Cordoba, Spain
    Clin Dev Immunol 2012:974648. 2012
    ....
  10. doi request reprint Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases
    C Lopez-Pedrera
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Cordoba, Spain
    Lupus 17:904-15. 2008
    ..The increasing data available suggests that when treating patients with these autoimmune disorders, paying attention to the increased risk of cardiovascular disease is essential...
  11. doi request reprint Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome
    Chary Lopez-Pedrera
    Research Unit and Rheumatology Department, University Hospital Reina Sofia, Avenida Menéndez, Pidal s n, E 14004 Cordoba, Spain
    Arthritis Rheum 62:869-77. 2010
    ....
  12. doi request reprint Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome
    Chary Lopez-Pedrera
    IMIBIC, Hospital Reina Sofia, Avenida Menendez Pidal s n, E 14004 Cordoba, Spain
    Ann Rheum Dis 70:675-82. 2011
    ..This study delineates the global effects of fluvastatin on the prothrombotic tendency of monocytes from APS patients...
  13. ncbi request reprint Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies
    C Lopez-Pedrera
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Cordoba, Spain
    Leukemia 20:1331-40. 2006
    ..This review attempts to establish a cellular and molecular causal link between cancer coagulopathy, angiogenesis and tumor progression in hematological malignancies...
  14. ncbi request reprint [Pathogenic mechanisms of thrombosis in neoplasia: therapeutic implications]
    Chary Lopez-Pedrera
    Unidad de Investigación y Servicio de Hematología Hospital Universitario Reina Sofía Córdoba España
    Med Clin (Barc) 122:190-6. 2004
    ..This review discuss the current status in pharmacological interventions to block thrombogenicity and angiogenesis in the treatment of cancer...
  15. ncbi request reprint Promyelocytic leukemia retinoid signaling targets regulate apoptosis,tissue factor and thrombomodulin expression
    Chary Lopez-Pedrera
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Avda Menendez Pidal s n, E 14004 Cordoba, Spain
    Haematologica 89:286-95. 2004
    ....
  16. ncbi request reprint Antiphospholipid-mediated thrombosis: interplay between anticardiolipin antibodies and vascular cells
    Chary Lopez-Pedrera
    Research Unit and Hematology Department, Reina Sofia University Hospital, Cordoba, Spain
    Clin Appl Thromb Hemost 12:41-5. 2006
    ..Increased levels of beta-thrombomodulin, and microvesicle formation seem to support this hypothesis. Activated platelets may contribute to thrombosis by persistent exposure of a procoagulant surface...
  17. doi request reprint Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis
    Chary Lopez-Pedrera
    Hospital Universitario Reina Sofia, Cordoba, Spain
    Arthritis Rheum 58:2835-44. 2008
    ..In this study, using proteomic techniques, we evaluated changes in protein expression of monocytes from patients with antiphospholipid syndrome (APS) related to the pathophysiology of the syndrome...
  18. ncbi request reprint Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK
    Chary Lopez-Pedrera
    Unidad de Investigacion, Reina Sofia University Hospital, Avda Menendez Pidal s n, E 14004 Cordoba, Spain
    Arthritis Rheum 54:301-11. 2006
    ..This study was undertaken to investigate the intracellular signals induced by aPL that mediate TF activation in monocytes from APS patients...
  19. ncbi request reprint Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors
    Emilio Siendones
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Cordoba, Spain
    Hematol Oncol 25:30-7. 2007
    ..Thus, we propose that each AML patient should have an individually tailored combination treatment...
  20. doi request reprint Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment
    Carlos Pérez-Sánchez
    Instituto Maimonides de Investigación Biomédica de Córdoba IMIBIC Reina Sofia Hospital, Cordoba, Spain
    Blood 119:5859-70. 2012
    ....
  21. doi request reprint MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia
    Nuria Barbarroja
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Cordoba, Spain
    Br J Haematol 142:27-35. 2008
    ..Taken together, our data suggest a new role of MEK/ERK pathway in the pathogenesis of APL, thus supporting the use of MEK/ERK inhibitors as an efficient therapeutic strategy for this haematological malignancy...
  22. doi request reprint Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab
    Amanda Cañas
    Oncology Department, Maimonides Institute of Biomedical Research IMIBIC, Reina Sofia Hospital, University of Cordoba, Spain Spanish Cancer Network RTICC, Instituto de Salud Carlos III, Madrid, Spain Electronic address
    Biochim Biophys Acta 1862:601-10. 2016
    ..In conclusion, our data provide evidence of molecular mechanisms contributing to the progression of HER2+ breast cancers and could facilitate the development of therapeutic options to counteract resistance to anti-HER2 therapies. ..
  23. doi request reprint Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment
    Patricia Ruiz-Limón
    Maimonides Institute for Research in Biomedicine of Cordoba IMIBIC Reina Sofia University Hospital University of Cordoba, Cordoba, Spain
    Ann Rheum Dis 74:1450-8. 2015
    ..We investigated potential mechanisms involved in the efficacy of fluvastatin in preventing atherothrombosis in SLE...
  24. ncbi request reprint Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia
    Nuria Barbarroja
    Unidad de Investigacion Hospital Reina Sofía, Cordoba, Spain
    Leuk Lymphoma 48:1187-99. 2007
    ..Our results show a coordinated deregulation of cellular receptors, proangiogenic factors, and intracellular pathways in leukemia cells, which may help to design mechanism-based combinations of single transduction-related therapies...
  25. doi request reprint Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus
    Carlos Pérez-Sánchez
    Maimonides Institute for Research in Biomedicine of Cordoba IMIBIC Reina Sofia University Hospital University of Cordoba, Cordoba, Spain
    Ann Rheum Dis 74:1441-9. 2015
    ....
  26. doi request reprint Proteomic approaches to evaluate protein S-nitrosylation in disease
    Laura M Lopez-Sanchez
    Research Unit, Instituto Maimonides de Investigacion Biomedica de Cordoba IMIBIC, Hospital Reina Sofia, Universidad de Cordoba, Spain
    Mass Spectrom Rev 33:7-20. 2014
    ..Here we review novel refinements and improvements to these methods, and some recent studies of the S-nitrosoproteome in disease...
  27. doi request reprint Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia
    Nuria Barbarroja
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Cordoba, Spain
    Exp Hematol 37:679-91. 2009
    ....
  28. pmc Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells
    Araceli Valverde
    Oncology Department, Maimonides Institute of Biomedical Research IMIBIC, Reina Sofia Hospital, University of Cordoba, Cordoba, Spain Spanish Cancer Network RTICC, Instituto de Salud Carlos III, Madrid, Spain
    PLoS ONE 10:e0131363. 2015
    ..Therefore, the simultaneous targeting of EGFR/VEGF and COX-2 may aid in blocking mCRC progression and improve the efficacy of existing therapies in colorectal cancer. ..
  29. ncbi request reprint [Intracellular mechanisms involved in the angiogenic process in hematological malignancies]
    Nuria Barbarroja
    Unidad de Investigacion, Servicio de Hematologia, Hospital Universitario Reina Sofia, Cordoba, Spain
    Med Clin (Barc) 130:585-90. 2008
    ..This review discusses the current status in pharmacological interventions to block angiogenesis in the treatment of these neoplasias...
  30. doi request reprint Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα
    Carmen Castro-Villegas
    Maimonides Institute for Research in Biomedicine of Cordoba IMIBIC Reina Sofia University Hospital University of Cordoba, Cordoba, Spain
    Arthritis Res Ther 17:555. 2015
    ..The aim of this study was to investigate serum miRNA levels as predictive biomarkers of response to anti-TNFα therapy in RA patients...
  31. doi request reprint VEGF targeted therapy in acute myeloid leukemia
    Antonio Rodriguez-Ariza
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Instituto Maimonides de Investigacion Biomedica de Cordoba, IMIBIC, Spain
    Crit Rev Oncol Hematol 80:241-56. 2011
    ..The benefits of these VEGF targeted agents and their current stage of development as novel anti-antiangiogenic therapies in AML are discussed in this review...
  32. doi request reprint AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia
    Nuria Barbarroja
    Fundacion IMABIS, Hospital Universitario Virgen de la Victoria, Malaga, Spain
    Exp Hematol 38:641-52. 2010
    ..It is not known, however, about the efficacy of this inhibitor in the treatment of AML. Therefore, we investigated the effect of AEE788 in the treatment of three human AML cell lines and seven AML patient samples...
  33. pmc CoCl2, a mimic of hypoxia, induces formation of polyploid giant cells with stem characteristics in colon cancer
    Laura M Lopez-Sanchez
    Oncology Department, Maimonides Institute of Biomedical Research IMIBIC, Reina Sofia Hospital, University of Cordoba, Cordoba, Spain Spanish Cancer Network RTICC, Instituto de Salud Carlos III, Madrid, Spain
    PLoS ONE 9:e99143. 2014
    ..The molecular mechanisms involved, including the stabilization of HIF-1 α, the involvement of p53/p47 isoform and cell cycle arrest at G2, suggest novel targets to prevent tumor relapse and treatment failure in colon cancer. ..
  34. doi request reprint Proteomics insights into deregulated protein S-nitrosylation and disease
    Laura M Lopez-Sanchez
    Cell Biology Department, Instituto Maimonides de Investigacion Biomedica de Cordoba IMIBIC, Hospital Reina Sofia, Universidad de Cordoba, Spain
    Expert Rev Proteomics 9:59-69. 2012
    ....
  35. ncbi request reprint Pharmacological impairment of s-nitrosoglutathione or thioredoxin reductases augments protein S-Nitrosation in human hepatocarcinoma cells
    Laura M Lopez-Sanchez
    Unidad de Investigacion, Hospital Universitario Reina Sofia, Instituto Maimonides de Investigacion Biomedica de Cordoba, IMIBIC, 14004, Cordoba, Spain
    Anticancer Res 30:415-21. 2010
    ..Pharmacological interventions against these enzyme systems might represent valuable strategies to impair S-nitrosothiol (SNO) homeostasis in tumour cells...
  36. doi request reprint Increased dihydroceramide/ceramide ratio mediated by defective expression of degs1 impairs adipocyte differentiation and function
    Nuria Barbarroja
    Metabolic Research Laboratories, Wellcome Trust MRC Institute of Metabolic Science, Addenbrooke s Hospital, University of Cambridge, Cambridge, U K Instituto Maimónides de Investigación Biomédica de Córdoba, Reina Sofia University Hospital, Cordoba, Spain
    Diabetes 64:1180-92. 2015
    ..These data identify DEGS1 as a new potential target to restore adipose tissue function and prevent obesity-associated metabolic disturbances. ..
  37. ncbi request reprint Role of NF-kappaB activation and nitric oxide expression during PGE protection against d-galactosamine-induced cell death in cultured rat hepatocytes
    Dalia Fouad
    Unidad Clínica Aparato Digestivo, Hospital Universitario Reina Sofia, Cordoba, Spain
    Liver Int 24:227-36. 2004
    ..The present study shows that the cytoprotection by PGE1 against D-GalN-induced apoptosis was related to NF-kappaB-dependent iNOS expression...
  38. ncbi request reprint PGE1 abolishes the mitochondrial-independent cell death pathway induced by D-galactosamine in primary culture of rat hepatocytes
    Emilio Siendones
    Clinical Unit of Digestive Apparatus, University Hospital Reina Sofia, Cordoba, Spain
    J Gastroenterol Hepatol 20:108-16. 2005
    ..In addition, we evaluated if PGE1 was able to modulate different parameters related to D-GalN-induced apoptosis in cultured rat hepatocytes...
  39. ncbi request reprint PGE1-induced NO reduces apoptosis by D-galactosamine through attenuation of NF-kappaB and NOS-2 expression in rat hepatocytes
    Emilio Siendones
    Unidad de Investigacion, Unidad Clínica Aparato Digestivo, Hospital Universitario Reina Sofia, Cordoba, Spain
    Hepatology 40:1295-303. 2004
    ..Therefore, a dual role for NO in PGE1-treated D-GalN-induced toxicity in hepatocytes is characterized by a rapid NO release that attenuates the late and proapoptotic NOS-2 expression...
  40. ncbi request reprint Role of nitric oxide in D-galactosamine-induced cell death and its protection by PGE1 in cultured hepatocytes
    Emilio Siendones
    Unidad de Investigacion, Servicio Aparato Digestivo, Hospital Universitario Reina Sofi a, Av Menendez Pidal s n, E 14004, Cordoba, Spain
    Nitric Oxide 8:133-43. 2003
    ..The present study suggests that low NO production induced by PGE(1) preadministration reduces D-GalN-induced cell death through its capacity to reduce iNOS expression and NO production caused by the hepatotoxin...
  41. ncbi request reprint Tumour necrosis factor-alpha and nitric oxide mediate apoptosis by D-galactosamine in a primary culture of rat hepatocytes: exacerbation of cell death by cocultured Kupffer cells
    Amira Mohamed Kamal ElSaid Abou-Elella
    Unidad Cernica Aparto Digestivo, Hospital Universitario Reina Sofia, Cordoba, Spain
    Can J Gastroenterol 16:791-9. 2002
    ..Prostaglandin E1 (PGE1) reduces cell death in experimental and clinical liver dysfunction...
  42. ncbi request reprint Regulation of parathyroid vitamin D receptor expression by extracellular calcium
    Bartolome Garfia
    Departamento de Medicina y Cirugia Animal, Universidad de Cordoba, 14004 Cordoba, Spain
    J Am Soc Nephrol 13:2945-52. 2002
    ..In conclusion, our study shows that extracellular Ca regulates VDR expression by parathyroid cells independently of CTR and that by this mechanism hypocalcemia may prevent the feedback of CTR on the parathyroids...